http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2398572-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-175 |
| filingDate | 2009-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b675dffee7b5ec225c022bbb8a6dce1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b44e3a95a93c3b8af0100c3a9f3d4aa3 |
| publicationDate | 2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2398572-C1 |
| titleOfInvention | Method of treating patients with type 2 diabetes mellitus |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to endocrinology and concerns treatment of type 2 diabetes mellitus. That is ensured by simultaneous administration of the preparations of the groups: metformin, sulphonylurea, glitazone and incretin in the developed regimens and dosages. n EFFECT: method provides higher clinical effectiveness and reduced time of treatment, and less by-effects due to involvement of all the links of pathogenesis of type 2 diabetes mellitus. n 1 ex, 1 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2485952-C2 |
| priorityDate | 2009-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 151.